JZ19

JZ19 reduces the LDH and ROS levels, and exhibits antioxidant activity against oxygen-glucose deprivation (OGD) -induced cardiomyocyte injury. JZ19 reverses Isoproterenol (HY-B0468) -induced cardiomyocyte hypertrophy and apoptosis through PI3K-AKT-GSK3β signaling pathway. JZ19 alleviates Isoproterenol (HY-B0468) -induced heart failure in mouse models[1].

Product Specifications

UNSPSC

12352005

Target

Akt; Apoptosis; GSK-3; PI3K

Related Pathways

Apoptosis; PI3K/Akt/mTOR; Stem Cell/Wnt

Field of Research

Cardiovascular Disease

Smiles

[H][C@@]1([C@@]2([C@@H](OC=C1)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)[H])[C@@H]([C@H]4[C@@]2(O4)COC5=CC=C(C=C5)C(F)(F)F)O

Molecular Formula

C22H25F3O10

Molecular Weight

506.42

References & Citations

[1]Liu H, et al., Structure Optimization of Natural Product Catalpol to Obtain Novel and Potent Analogs against Heart Failure. J Med Chem. 2025 Feb 27;68 (4) :4540-4560.